RecruitingNCT05551416

The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer

Research and Development of New Strategies for the Early Detection and Prevention of Gastric Cancer in the Spanish Population: EpiGASTRIC/EDGAR Project.


Sponsor

EDUARDO ALBENIZ

Enrollment

1,200 participants

Start Date

Sep 9, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

This study is a multicenter, prospective cohort study, which are planned to enroll at least 600 patients who diagnosed the primary gastric cancer (GC); around 50 patients with premalignant gastric lesions (PGLs) and early gastric neoplasias (EGC) treated by endoscopy resection; and no less than 600 healthy normal cohort participants, for more than 18 months in the Spanish population. All participants who enrolled in this registry will be questioned by the life habits survey; and clinical data and biological samples of these participants were analyzed in order to look for new diagnostic tools. The aim of this study is to evaluate clinical, endoscopic and molecular approaches to identify individuals with high-risk of GC. Thus, it would be allow the adoption of preventive measures to reduce mortality through early detection and/or the reduction of its incidence.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Adults over 18 years-old.
  • EDGAR 1 cohort: symptomatic patients undergoing a diagnostic gastroscopy for a prevalence study of PGLs.
  • EDGAR 2 cohort: PGLs and early GC with indication for endoscopic resection.
  • EPIGASTRIC cohort: patients diagnosed with GC.
  • CONTROL cohort: patients without gastric pathology or a familial history of GC, obtained from the EDGAR 1.

Exclusion Criteria5

  • Refusal of the patient to participate in the study.
  • Medical, psychological or legal inability of the patient to enter the study.
  • EDGAR1: Previous diagnosis of PGLs, previous gastric surgery, contraindication for gastroscopy or taking biopsies.
  • EDGAR 2: Contraindication for resection/biopsy.
  • EPIGASTRIC: gastric neoplasm other than adenocarcinoma.

Interventions

OTHERIdentification of risk factors

Demographics, life habits and risk factors studies

OTHERCharacterization of premalignant gastric lesions

Identification and characterization of premalignant gastric lesions through high definition endoscopic study. Concordance between endoscopic and histological classifications

OTHERIdentification of biomarkers

Multiomic studies

OTHERIdentification of gastric cancer hereditary predisposition

Genomic studies for the identification of individuals with hereditary GC predisposition


Locations(15)

Hospital Comarcal de Inca

Palma de Mallorca, Balearic Islands, Spain

Hospital de Llevant

Porto Cristo, Balearic Islands, Spain

Hospital General de Granollers

Granollers, Barcelona, Spain

Consorci Sanitari de Terrassa

Terrassa, Barcelona, Spain

Hospital Santos Reyes

Aranda de Duero, Burgos, Spain

Hospital de Mérida

Mérida, Extremadura, Spain

Hospital Universitario de Ourense

Ourense, Galicia, Spain

Hospital Puerta de Hierro

Majadahonda, Madrid, Spain

Hospital Universitario de Navarra

Pamplona, Navarre, Spain

Hospital Universitario Central de Asturias

Oviedo, Principality of Asturias, Spain

Hospital Clínic de Barcelona

Barcelona, Spain

Hospital Universitario de Burgos

Burgos, Spain

Hospital Josep Trueta

Girona, Spain

Hospital Clínico Universitario Lozano Blesa

Zaragoza, Spain

Hospital Universitario Miguel Servet

Zaragoza, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05551416


Related Trials